Literature DB >> 15780445

Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children.

Jamie Findlow1, Ann Lowe, Sarah Deane, Paul Balmer, Germie van den Dobbelsteen, Maureen Dawson, Nick Andrews, Ray Borrow.   

Abstract

Though meningococcal conjugate vaccines are effective against serogroup C, there is currently no vaccine solution for serogroup B disease. PorA outer membrane protein (OMP) is a potential serogroup B vaccine candidate. A hexavalent PorA outer membrane vesicle (OMV) vaccine has been evaluated in phase I and II trials with promising results. However, considerable sequence variation occurs in the variable regions (VRs) encoding these serosubtypes. By using five wild type P1.19,15 variant strains we examined the serum bactericidal antibody (SBA) titres from sera collected from toddlers and school children pre- and post-vaccination. The numbers of subjects with SBA titres of <4, 4 and > or = 8 varied greatly between the different strains. This was also reflected when > or = 4-fold rises in SBA titres were examined. This finding in sera from toddlers and school children may have implications for PorA based vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780445     DOI: 10.1016/j.vaccine.2004.11.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin.

Authors:  S Lear; E Eren; J Findlow; R Borrow; D Webster; S Jolles
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

2.  Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines.

Authors:  Brian D Plikaytis; Maria Stella; Giuseppe Boccadifuoco; Lisa M DeTora; Mauro Agnusdei; Laura Santini; Brunella Brunelli; Luca Orlandi; Isabella Simmini; Marzia Giuliani; Morgan Ledroit; Eva Hong; Muhamed-Kheir Taha; Kim Ellie; Gowrisankar Rajam; George M Carlone; Heike Claus; Ulrich Vogel; Ray Borrow; Jamie Findlow; Stefanie Gilchrist; Paola Stefanelli; Cecilia Fazio; Anna Carannante; Jan Oksnes; Elisabeth Fritzsønn; Anne-Marie Klem; Dominique A Caugant; Raquel Abad; Julio A Vázquez; Rino Rappuoli; Mariagrazia Pizza; John J Donnelly; Duccio Medini
Journal:  Clin Vaccine Immunol       Date:  2012-08-08

3.  Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.

Authors:  Jay Lucidarme; Maurizio Comanducci; Jamie Findlow; Stephen J Gray; Edward B Kaczmarski; Malcolm Guiver; Pamela J Vallely; Philipp Oster; Mariagrazia Pizza; Stefania Bambini; Alessandro Muzzi; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

4.  Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.

Authors:  Jamie Findlow; Stephen Taylor; Audun Aase; Rachel Horton; Robert Heyderman; Jo Southern; Nick Andrews; Rita Barchha; Ewan Harrison; Ann Lowe; Emma Boxer; Charlotte Heaton; Paul Balmer; Ed Kaczmarski; Philipp Oster; Andrew Gorringe; Ray Borrow; Elizabeth Miller
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

5.  Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay.

Authors:  Jamie Findlow; Ann Holland; Nick Andrews; Vincent Weynants; Franklin Sotolongo; Paul Balmer; Jan Poolman; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.